london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

The effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema

Poster Details

First Author: M.Douvali GREECE

Co Author(s):    I. Chatziralli   P. Theodossiadis   V. Liarakos   K. Chatzistefanou   E. Giannakaki   A. Rouvas   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the impact of macular ischemia on the functional and anatomical outcome after intravitreal injections of ranibizumab for the treatment of diabetic macular edema (DME).

Setting:

Β΄Department of Ophthalmology, ATTIKON Hospital ,University of Athens,Greece

Methods:

Participants in our study were 49 consecutive patients with diabetes mellitus, who were grouped in two groups, based on the presence of ischemia on fluorescein angiography: i) Non ischemic group (n=32) and ii) Ischemic group (n=17). All participants underwent best corrected visual acuity (BCVA) measurement, slit-lamp examination, fundoscopy and optical coherence tomography at baseline and at all visits of the follow-up. All patients were treated with intravitreal ranibizumab 0.5 mg and were followed-up for 6 months. The main outcome measures were changes in visual acuity and central foveal thickness (CFT).

Results:

There was a statistically significant improvement in VA (p=0.01) and CFT (p<0.0001) between baseline and the end of the follow-up in the non-ischemic group, while in the ischemic group there was no significant difference in VA (p=0.480) but CFT differed significantly (p<0.0001) at the 6-month follow-up. The number of injections during the 6-month follow-up was 3.75±0.72 in the non-ischemic and 3.82±0.73 in the ischemic group (p=0.724) and no vision-threatening complications were observed in any group.

Conclusions:

Macular ischemia may have a negative impact on functional outcomes 6 months after intravitreal ranibizumab treatment in patients with DME, but has no effect on anatomical outcomes. Nevertheless, ranibizumab did not seem to negatively influence the VA, the CFT or the progression of macular ischemia, as confirmed at the end of the follow-up.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy